

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : David B. AGUS
Application No. : 10/625,152
Filed : July 23, 2003
For : Use of Benzothiopenes to Treat and Prevent Prostate Cancer

Examiner : James D. ANDERSON
Art Unit : 1614
Docket No. : 67789-19


DECLARATION OF DAVID B. AGUS, M.D., UNDER 37 CFR 1.131

Dear Sir:

I, David B. Agus, declare and state as follows:

1. Cedars-Sinai Medical Center is the assignee of the entire right, title and interest of the above-referenced patent application.
2. I am the sole inventor named in the above-referenced patent application.
3. On June 17, 2002, Koo Nguyen, the Clinical Research Development Manager for the Prostate Cancer Center at Cedars-Sinai Medical Center, sent an electronic mail message to me confirming that a patient will be taking raloxifene at 180 mg/day. The message has been redacted to remove the patient's name solely to protect the patient's privacy. A copy of the electronic mail message with the redaction is appended hereto as "Exhibit A." This demonstrates that I had completed conception of the invention and reduced the invention to practice in the United States as described and claimed in the above-referenced application by at least June 17, 2002.
4. I hereby declare that all statements made of my own knowledge are true and that all statements made on information and belief are believed to be true, and further, that these statements are made with the knowledge that willful false

statements and the like so made are punishable by fine or imprisonment, or both, under Section 10001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application and any patent issued thereon.



David B. AGUS, M.D.

Dated: 7/16/07